Galmed Pharmaceuticals Ltd.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) is a clinical-stage biopharmaceutical company focused on the development of therapeutics for liver, metabolic, inflammatory, and oncological diseases. The company develops its lead product candidate Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate designed for the oral treatment of metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) and fibrosis in patients who are overweight or obese with prediabetes or type II diabetes; Aramchol is also being evaluated for HIV-associated non-alcoholic fatty liver disease and lipodystrophy through the ARRIVE study, as well as in combination with standard-of-care agents like Stivarga (regorafenib) for gastrointestinal oncology indications including metastatic colorectal cancer, hepatocellular carcinoma, and cholangiocarcinoma. In addition, Galmed advances Amilo-5MER, a novel five-amino-acid synthetic peptide targeting serum amyloid A (SAA) fibrillation for chronic inflammatory conditions such as ulcerative colitis, which recently initiated a Phase 1 first-in-human trial assessing safety, tolerability, and pharmacokinetics; the company is also exploring earlier-stage candidates like Icomidocholic acid for fibrosis, Steamchol for gallstones, and MyBiotics for NASH. Recent advancements include the publication in March 2025 of Phase 3 ARMOR open-label study results in the Journal of Hepatology demonstrating Aramchol's robust anti-fibrotic activity with 65% fibrosis improvement via paired biopsies and 100% via AI evaluation at week 48; preclinical data announced in November 2025 showing Aramchol enhances Stivarga efficacy and overcomes resistance in GI tumor models, supporting a planned Phase 1/2 trial with VCU Massey Comprehensive Cancer Center in early 2026. Galmed reported positive top-line results from the November 2025 AM-001 Phase 1 bioavailability study of Aramchol Meglumine and is developing novel sublingual and subcutaneous formulations to enable fixed-dose MASH combinations and higher systemic exposure for cardiometabolic indications; the company raised approximately $9.3 million through equity line and ATM facilities during 2025, ending Q3 with $19.2 million in cash and a quarterly burn of about $1.5 million. It maintains a license agreement with Samil Pharma Co., Ltd. for Aramchol commercialization in South Korea and a collaboration with Virginia Commonwealth University for oncology applications. Founded in 2000 and headquartered at 16 Abba Hillel Road, Ramat Gan, Israel, Galmed operates primarily in the biotechnology sector with corporate offices in the United States to support regulatory and clinical interactions; the company targets patients with progressive liver diseases, cardiometabolic disorders, chronic inflammation, and unmet oncology needs across global markets.
Tissue Dynamics and Galmed Unveil Unknown Metabolic Pathway for Cardiac Fibrosis and Heart Failure which Supports the Development of Aramchol for Cardiac Fibrosis
Galmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA) 300mg
Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics
Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Short Interest Update
Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain Cancers
Galmed Stock Soars On Brain-Penetrating Aramchol Formulation
Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025
Surrozen (NASDAQ:SRZN) & Galmed Pharmaceuticals (NASDAQ:GLMD) Financial Review
Short Interest in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Decreases By 15.8%
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification
Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting
Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH
Galmed Issues CEO Letter to Shareholders
Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine
Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro
Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
Galmed Announces Digital Asset Management Strategy to Enhance Capital Efficiency and Drive Shareholder Value
Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH